Dr Reddy’s gets EIR from US FDA for 2 units at Medak

As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings

Drug firm Dr Reddy’s Laboratories (DRL) has received establishment inspection report (EIR) from the US health regulator for its two units at Medak district in Telangana.

In an earlier filing to the bourses on March 9, the drug firm had said it had received five observations from the US Food and Drug Administration (US FDA) for its API Hyderabad plant 3 at Medak district.

On March 16, the company intimated the bourses that it had been issued a Form 483 with four observations for its API Hyderabad plant 1 at Jinnaram Mandal, Medak district.

“…we have received an establishment inspection report (EIR) from the USFDA, for both of the above-referred facilities,” DRL said in a filing to BSE.

As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.